Eli Lilly – iF! - Inovativna farmaceutska inicijativa

About Us

Association

Mission and Vision

Strategy and Objectives

Organisational Structure

Statute of the Innovative Pharmaceutical Initiative

Business Ethics

Code of Conduct of Innovative Pharmaceutical Companies

Public Disclosures

iF! Members Disclosures

Financial reports

Frequently Asked Questions

Strategic Projects

HeMED

Serialization of medicines / NMVO

Clinical practice guidelines and monitoring treatment outcomes

Initiatives

WeWontRest

Treatment Outcomes 2020/30

Clinical trials

Useful Links

Useful links list

Source of information on vaccines and vaccination

Members

News

02/2021

Advances were preceded by many failures

Advances in the research and development of therapeutic options witnessed in recent years...

02/2021

Treatment Outcomes

There are significant differences in treatment outcomes across European Union member states, and...

02/2021

The treatment of hematologic malignant diseases in Croatia has significantly improved

Thanks to new knowledge and the discovery of new medicines that had previously...

Innovative Pharmaceutical Initiative – iF!

Florijana Andrašeca 20, 10000 Zagreb, Croatia

+385 1 2020 434

19

innovative pharmaceutical companies

703

employees

56

% of the Croatian medicines market

32

MM Eur of transferred value in 2024

30

years of the Association’s activity

Homepage

> Members

> Eli Lilly

Company title

Eli Lilly

/ Eli Lilly Hrvatska d.o.o.

Headquarters

Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA

Croatia office headquarters

Ulica grada Vukovara 269 G, 10000 Zagreb, Croatia

Croatia office contact

Croatia number of employees

29

Therapeutic areas

–

Alzheimer’s disease

–

Obesity

–

Dermatology

–

Diabetes

–

Haematology

–

Immunology

–

Cardio-metabolic diseases

–

Neurology

–

Oncology

Company claim

"A medicine company that puts health above all"

Company URL

Members

19

innovative pharmaceutical companies

703

employees

56

% of the Croatian medicines market

32

MM Eur of transferred value in 2024

30

years of the Association’s activity